The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.

Tag:

Pfizer

Latest Headlines

Latest Headlines

Kathrin Jansen named head of Pfizer vaccine R&D

Pfizer has a new vaccines R&D head in Kathrin Jansen, who will begin at the post on June 1. Previously CSO of Pfizer's vaccine research and early development, Jansen will report to global R&D president Mikael Dolsten and work out of Pfizer's Pearl River, New York research site.

Big Pharma-backed Dutch immuno-oncology player eyes €100M Nasdaq IPO

A Dutch immuno-oncology player that has received venture funding from Johnson & Johnson, Novartis and Pfizer is preparing to list on Nasdaq. The company--Merus--hopes to raise upward of €100 million ($107 million) to advance its pipeline of bispecific IgG antibodies into the clinic and through early-phase trials.

Expired Pfizer contraceptives recalled after supply chain fumble

A Canadian drug distributor began recalling a small quantity of Pfizer birth control pills this week after it accidentally shipped out expired product. Pfizer credited the company with quick action, but it is the kind of issue that in the past has led to litigation against drugmakers over unwanted pregnancies.

Pfizer, Merck KGaA suit up for Xalkori marketing wave

When Pfizer teamed up with Merck KGaA on lung cancer, the headlines zeroed in on the sexiest part of the $2.85 billion deal: their immuno-oncology plans. The two companies will work together on cancer-fighters in the PD-L1 arena, one of the hottest fields in pharma these days, including a Phase II Merck drug.

UPDATED: Hospira, soon to be part of Pfizer, spanked again by the FDA

When Pfizer announced its $15 billion deal to buy sterile injectable specialist Hospira, execs said they had studied FDA concerns over Hospira manufacturing before pulling the trigger. But Hospira just keeps giving Pfizer new lessons. Today, the FDA posted a warning letter it recently sent to Hospira CEO F. Michael Ball for a plant in Italy.

Pfizer wants Canadians to think EpiPen. What else but a hockey partnership?

Got severe food allergies, Montreal Canadiens fans? Worry not: Thanks to Pfizer, anaphylaxis med EpiPen is near.

Pfizer shutters vaccine sales business in China after Prevenar setback

As it beefs up its vaccines business, Pfizer's looking to bolster revenue from the top-selling Prevenar family of shots. But on that front, it's come up against a roadblock in China--and so it's shutting down its vaccines marketing there.

Pfizer pulls vaccines sales business out of China

Pfizer said on Thursday that it would be pulling its vaccines sales business out of China after the import license of Prevenar, its top-selling treatment, was not renewed, Reuters reported.

Pfizer halts Prevenar operations in China as import renewal fails to materialize

Pfizer Inc. has halted vaccine operations in China following failure to get a license renewal for its existing Prevenar shot and as a new wider coverage of the same vaccine for pneumococcal diseases also awaits approval, highlighting issues with the approval process in the Middle Kingdom as well as fierce competition in the vaccines space regionally.

Australia's reimbursement cost battle hits cancer drug access

Australia's reimbursement agency has lagged developed country counterparts in paying for newly approved new cancer therapies, highlighting problems at the tail end of a system that patients and industry complain is broken.